Similar articles for PMID: 22872740

Year	Number of Results
1985	1
1992	1
1996	1
1998	2
2000	2
2001	4
2003	2
2004	2
2005	4
2006	2
2007	1
2009	4
2010	3
2011	6
2012	5
2013	7
2014	7
2015	11
2016	5
2017	2
2018	5
2019	2
2020	8
2021	7
2022	2
2023	1
2024	0

1

Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.

Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, Lin K. Boswell CA, et al. J Nucl Med. 2012 Sep;53(9):1454-61. doi: 10.2967/jnumed.112.103168. Epub 2012 Aug 7. J Nucl Med. 2012. PMID: 22872740 Free article.

2

Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.

Boswell CA, Yadav DB, Mundo EE, Yu SF, Lacap JA, Fourie-O'Donohue A, Kozak KR, Ferl GZ, Zhang C, Ho J, Ulufatu S, Khawli LA, Lin K. Boswell CA, et al. Oncotarget. 2019 Oct 22;10(58):6234-6244. doi: 10.18632/oncotarget.27263. eCollection 2019 Oct 22. Oncotarget. 2019. PMID: 31692898 Free PMC article.

3

Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.

Lütje S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, Fracasso G, Colombatti M, Boerman OC, Heskamp S. Lütje S, et al. J Nucl Med. 2018 Mar;59(3):494-501. doi: 10.2967/jnumed.117.196279. Epub 2017 Nov 16. J Nucl Med. 2018. PMID: 29146698 Free article.

4

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, Fourie A, Kozak KR, Fuji R, Polakis P, Khawli LA, Lin K. Boswell CA, et al. Br J Pharmacol. 2013 Jan;168(2):445-57. doi: 10.1111/j.1476-5381.2012.02138.x. Br J Pharmacol. 2013. PMID: 22889168 Free PMC article.

5

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.

Williams SP, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, Go M, Vanderbilt AN, Gill HS, Miao L, Goldsmith J, Rubinfeld B, Mao W, Firestein R, Yu SF, Marik J, Terwisscha van Scheltinga AG. Williams SP, et al. Oncotarget. 2016 May 3;7(18):25103-12. doi: 10.18632/oncotarget.8390. Oncotarget. 2016. PMID: 27029064 Free PMC article.

6

Targeting tomoregulin for radioimmunotherapy of prostate cancer.

Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto C, Wada K, Schulze M, Müller-Tiemann B, Parry G, Dinter H. Zhao XY, et al. Cancer Res. 2005 Apr 1;65(7):2846-53. doi: 10.1158/0008-5472.CAN-04-4019. Cancer Res. 2005. PMID: 15805286

7

Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.

Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Buchsbaum DJ, et al. Cancer Res. 1992 Feb 1;52(3):637-42. Cancer Res. 1992. PMID: 1732052

8

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E. DiPippo VA, et al. Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18. Prostate. 2015. PMID: 25327986

9

Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.

Razumienko EJ, Scollard DA, Reilly RM. Razumienko EJ, et al. J Nucl Med. 2012 Dec;53(12):1943-50. doi: 10.2967/jnumed.112.106906. Epub 2012 Oct 24. J Nucl Med. 2012. PMID: 23096164 Free article.

10

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA. Afar DE, et al. Mol Cancer Ther. 2004 Aug;3(8):921-32. Mol Cancer Ther. 2004. PMID: 15299075

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year